Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18414959 | 0.91 | TGFBR1 (0.77) | TGFBR1TGFBR2 | |
| SCHEMBL18397408 | 0.90 | TGFBR1 (0.85) | TGFBR1TGFBR2 | |
| SCHEMBL18414826 | 0.89 | TGFBR1 (1.00) | TGFBR1TGFBR2 | |
| SCHEMBL18397476 | 0.87 | TGFBR1 (1.00) | TGFBR1TGFBR2 | |
| SCHEMBL18397541 | 0.87 | TGFBR1 (1.00) | TGFBR1TGFBR2 | |
| SCHEMBL18397440 | 0.86 | TGFBR1 (1.00) | TGFBR1TGFBR2 | |
| SCHEMBL18397532 | 0.86 | TGFBR1 (1.00) | TGFBR1TGFBR2 | |
| SCHEMBL18397474 | 0.86 | TGFBR1 (1.00) | TGFBR1TGFBR2 | |
| SCHEMBL18397228 | 0.86 | TGFBR1 (0.84) | TGFBR1TGFBR2 | |
| SCHEMBL18397495 | 0.86 | TGFBR1 (1.00) | TGFBR1TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336761-B2 | TGFβ receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336761-B2 | TGFβ receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180215761-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180215761-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180215761-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-02 | — | — | US | disclosed |
| EP-3325484-A1 | TGF BETA RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017015425-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017015425-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336761-B2 | TGFβ receptor antagonist | TGFBR2, TGFBR1, SMAD2 | TGFBR1 2/4885TGFBR2 1/4885 |
| US-20180215761-A1 | TGF BETA RECEPTOR ANTAGONISTS | TGFBR2, TGFBR1, TGFB2 | TGFBR1 2/4885TGFBR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.